$12.05
Insights on Novocure Limited
Revenue is up for the last 4 quarters, 122.18M → 133.78M (in $), with an average increase of 3.0% per quarter
Netprofit is up for the last 3 quarters, -57.41M → -47.07M (in $), with an average increase of 10.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 112.8%
In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 159.8%
1.33%
Downside
Day's Volatility :4.27%
Upside
2.98%
9.79%
Downside
52 Weeks Volatility :87.0%
Upside
85.59%
Period | Novocure Limited | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -16.9% | -0.7% | 0.0% |
6 Months | -20.98% | 6.6% | 0.0% |
1 Year | -81.07% | 3.7% | -1.5% |
3 Years | -93.69% | 14.0% | -21.8% |
Market Capitalization | 1.3B |
Book Value | $3.39 |
Earnings Per Share (EPS) | -1.95 |
PEG Ratio | -0.47 |
Wall Street Target Price | 27.33 |
Profit Margin | -40.65% |
Operating Margin TTM | -33.64% |
Return On Assets TTM | -12.09% |
Return On Equity TTM | -51.53% |
Revenue TTM | 509.3M |
Revenue Per Share TTM | 4.79 |
Quarterly Revenue Growth YOY | 4.2% |
Gross Profit TTM | 423.6M |
EBITDA | -216.5M |
Diluted Eps TTM | -1.95 |
Quarterly Earnings Growth YOY | -0.06 |
EPS Estimate Current Year | -1.76 |
EPS Estimate Next Year | -1.83 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.48 |
What analysts predicted
Upside of 126.8%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 248.1M | ↑ 40.13% |
Net Income | -63.6M | ↑ 3.08% |
Net Profit Margin | -25.62% | ↑ 9.21% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 351.3M | ↑ 41.62% |
Net Income | -7.2M | ↓ 88.62% |
Net Profit Margin | -2.06% | ↑ 23.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 494.4M | ↑ 40.72% |
Net Income | 19.8M | ↓ 373.97% |
Net Profit Margin | 4.01% | ↑ 6.07% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 535.0M | ↑ 8.23% |
Net Income | -58.4M | ↓ 394.58% |
Net Profit Margin | -10.91% | ↓ 14.92% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 537.8M | ↑ 0.53% |
Net Income | -92.5M | ↑ 58.58% |
Net Profit Margin | -17.2% | ↓ 6.29% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 509.3M | ↓ 5.3% |
Net Income | -207.0M | ↑ 123.75% |
Net Profit Margin | -40.65% | ↓ 23.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 131.0M | ↓ 7.01% |
Net Income | -26.6M | ↑ 10.7% |
Net Profit Margin | -20.29% | ↓ 3.25% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 128.4M | ↓ 1.96% |
Net Income | -37.3M | ↑ 40.36% |
Net Profit Margin | -29.05% | ↓ 8.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 122.2M | ↓ 4.86% |
Net Income | -53.1M | ↑ 42.24% |
Net Profit Margin | -43.43% | ↓ 14.38% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 126.1M | ↑ 3.17% |
Net Income | -57.4M | ↑ 8.21% |
Net Profit Margin | -45.55% | ↓ 2.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 127.3M | ↑ 1.01% |
Net Income | -49.5M | ↓ 13.82% |
Net Profit Margin | -38.87% | ↑ 6.68% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 133.8M | ↑ 5.08% |
Net Income | -47.1M | ↓ 4.86% |
Net Profit Margin | -35.19% | ↑ 3.68% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 339.8M | ↑ 28.08% |
Total Liabilities | 227.5M | ↑ 49.96% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 479.4M | ↑ 41.1% |
Total Liabilities | 261.7M | ↑ 15.0% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 119.42% |
Total Liabilities | 575.5M | ↑ 119.93% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 8.32% |
Total Liabilities | 729.0M | ↑ 26.68% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 4.58% |
Total Liabilities | 750.5M | ↑ 2.95% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↓ 3.82% |
Total Liabilities | 783.6M | ↑ 4.42% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 0.99% |
Total Liabilities | 728.8M | ↑ 1.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 1.48% |
Total Liabilities | 750.5M | ↑ 2.97% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 1.45% |
Total Liabilities | 742.2M | ↓ 1.1% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 1.3% |
Total Liabilities | 743.3M | ↑ 0.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 1.09% |
Total Liabilities | 752.6M | ↑ 1.25% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 0.02% |
Total Liabilities | 783.6M | ↑ 4.12% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.9M | ↓ 94.37% |
Investing Cash Flow | -5.5M | ↓ 163.66% |
Financing Cash Flow | 69.4M | ↑ 1242.28% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 26.6M | ↓ 1527.35% |
Investing Cash Flow | -51.7M | ↑ 840.6% |
Financing Cash Flow | 61.7M | ↓ 11.08% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 99.1M | ↑ 272.46% |
Investing Cash Flow | -472.8M | ↑ 815.18% |
Financing Cash Flow | 440.2M | ↑ 613.69% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 82.8M | ↓ 16.53% |
Investing Cash Flow | -144.8M | ↓ 69.37% |
Financing Cash Flow | 25.7M | ↓ 94.16% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 30.8M | ↓ 62.8% |
Investing Cash Flow | -140.0M | ↓ 3.37% |
Financing Cash Flow | 15.5M | ↓ 39.73% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 22.4M | ↑ 42.24% |
Investing Cash Flow | -150.2M | ↓ 196.46% |
Financing Cash Flow | 4.2M | ↓ 11.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 116.53% |
Investing Cash Flow | -128.1M | ↓ 14.77% |
Financing Cash Flow | 3.4M | ↓ 18.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.7M | ↑ 351.23% |
Investing Cash Flow | 82.3M | ↓ 164.26% |
Financing Cash Flow | 5.2M | ↑ 52.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.7M | ↑ 35.93% |
Investing Cash Flow | -13.9M | ↓ 116.89% |
Financing Cash Flow | 7.5M | ↑ 44.16% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↓ 15.05% |
Investing Cash Flow | 17.3M | ↓ 224.19% |
Financing Cash Flow | 1.2M | ↓ 84.39% |
Sell
Neutral
Buy
Novocure Limited is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Novocure Limited | -12.81% | -20.98% | -81.07% | -93.69% | -71.46% |
Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Novocure Limited | NA | NA | -0.47 | -1.76 | -0.52 | -0.12 | NA | 3.39 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Novocure Limited | Buy | $1.3B | -71.46% | NA | -40.65% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
FMR Inc
Vanguard Group Inc
Capital Research & Mgmt Co - Division 3
BlackRock Inc
Baillie Gifford & Co Limited.
State Street Corporation
Novocure Limited’s price-to-earnings ratio stands at None
Read Morewe are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
Organization | Novocure Limited |
Employees | 1453 |
CEO | Mr. William F. Doyle |
Industry | Health Technology |